Green AJ, et al. - A randomised, controlled, double-blind, crossover trial is performed to examine the effectiveness and safety of clemastine fumarate as a treatment for patients with multiple sclerosis. This is the first study to document the effectiveness of a remyelinating drug for the treatment of chronic demyelinating injury in multiple sclerosis. These outcomes propose that myelin repair can be achieved even following prolonged damage.